Cope S - Search Results

1

Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia.

Cope S, Ayers D, Zhang J, Batt K, Jansen JP. Cope S, et al. BMC Med Res Methodol. 2019 Sep 2;19(1):182. doi: 10.1186/s12874-019-0823-8. BMC Med Res Methodol. 2019. PMID: 31477025 Free PMC article.

2

Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease--a network meta-analysis.

Cope S, Capkun-Niggli G, Gale R, Jardim JR, Jansen JP. Cope S, et al. Int J Chron Obstruct Pulmon Dis. 2011;6:329-44. doi: 10.2147/COPD.S18759. Epub 2011 Jun 8. Int J Chron Obstruct Pulmon Dis. 2011. PMID: 21697997 Free PMC article. Review.

3

Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison.

Cope S, Capkun-Niggli G, Gale R, Lassen C, Owen R, Ouwens MJ, Bergman G, Jansen JP. Cope S, et al. Value Health. 2012 May;15(3):524-33. doi: 10.1016/j.jval.2012.01.009. Epub 2012 Apr 11. Value Health. 2012. PMID: 22583463 Free article.

4

Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis.

Cope S, Zhang J, Williams J, Jansen JP. Cope S, et al. BMC Pulm Med. 2012 Jun 25;12:29. doi: 10.1186/1471-2466-12-29. BMC Pulm Med. 2012. PMID: 22732017 Free PMC article.

5

Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis.

Cope S, Kraemer M, Zhang J, Capkun-Niggli G, Jansen JP. Cope S, et al. Int J Chron Obstruct Pulmon Dis. 2012;7:415-20. doi: 10.2147/COPD.S31526. Epub 2012 Jul 5. Int J Chron Obstruct Pulmon Dis. 2012. PMID: 22848154 Free PMC article.

6

Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes.

Jansen JP, Cope S. Jansen JP, et al. Among authors: cope s. BMC Med Res Methodol. 2012 Oct 8;12:152. doi: 10.1186/1471-2288-12-152. BMC Med Res Methodol. 2012. PMID: 23043545 Free PMC article.

7

Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models.

Cope S, Ouwens MJ, Jansen JP, Schmid P. Cope S, et al. Value Health. 2013 Mar-Apr;16(2):403-17. doi: 10.1016/j.jval.2012.10.019. Epub 2013 Jan 26. Value Health. 2013. PMID: 23538193 Free article.

8

Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis.

Cope S, Donohue JF, Jansen JP, Kraemer M, Capkun-Niggli G, Baldwin M, Buckley F, Ellis A, Jones P. Cope S, et al. Respir Res. 2013 Oct 7;14(1):100. doi: 10.1186/1465-9921-14-100. Respir Res. 2013. PMID: 24093477 Free PMC article.

9

Quantitative summaries of treatment effect estimates obtained with network meta-analysis of survival curves to inform decision-making.

Cope S, Jansen JP. Cope S, et al. BMC Med Res Methodol. 2013 Dec 1;13:147. doi: 10.1186/1471-2288-13-147. BMC Med Res Methodol. 2013. PMID: 24289277 Free PMC article.

10

A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer.

Cope S, Zhang J, Saletan S, Smiechowski B, Jansen JP, Schmid P. Cope S, et al. BMC Med. 2014 Jun 5;12:93. doi: 10.1186/1741-7015-12-93. BMC Med. 2014. PMID: 24898705 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

188 results

Search Page

Filters